/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Vistagen Therapeutics Inc Share Price Today: Live Updates & Key Insights

Vistagen Therapeutics Inc share price today is $0.605, up 5.56%. The stock opened at $0.5976 against the previous close of $0.5976, with an intraday high of $0.63905 and low of $0.5868.

Vistagen Therapeutics Inc Share Price Chart

style
pb-0

Vistagen Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Vistagen Therapeutics Inc Share Price Performance

$0.605 0.0556(5.56%) VTGN at 13 Mar 2026 03:49 PM Biotechnology
Lowest Today 0.5868
Highest Today 0.63905
Today’s Open 0.5976
Prev. Close 0.5976
52 Week High 5.14
52 Week Low 0.43
Day’s Range: Low 0.5868 High 0.63905
52-Week Range: Low 0.43 High 5.14
1 day return -
1 Week return +5.72
1 month return +25.94
3 month return -85.54
6 month return -80.46
1 year return -76.49
3 year return -85.95
5 year return -99.06
10 year return -

Vistagen Therapeutics Inc Institutional Holdings

HHG PLC 10.51

Orbimed Advisors, LLC 7.72

TCG Crossover Management, LLC 6.76

Vanguard Group Inc 4.61

Vanguard Total Stock Mkt Idx Inv 2.93

Biotech Growth Ord 2.04

ADAR1 Capital Management LLC 1.57

Ikarian Capital, LLC 1.57

StemPoint Capital LP 1.56

Soleus Capital Management, L.P. 1.39

JPMorgan Chase & Co 1.37

BlackRock Inc 1.07

Vanguard Institutional Extnd Mkt Idx Tr 1.04

Luminus Management, LLC 0.88

Diadema Partners LP 0.88

Jane Street Group LLC 0.76

Geode Capital Management, LLC 0.75

AdvisorShares Psychedelics ETF 0.70

AdvisorShares Investments, LLC 0.52

Fidelity Extended Market Index 0.50

Two Sigma Investments LLC 0.49

Renaissance Technologies Corp 0.41

Dimensional Fund Advisors, Inc. 0.38

Two Sigma Advisers, LLC 0.35

BOOTHBAY FUND MANAGEMENT, LLC 0.34

iShares Micro-Cap ETF 0.20

DFA US Small Cap I 0.19

Blackrock Extended Mkt Fund CF 0.18

Extended Equity Market Fund K 0.15

Fidelity Total Market Index 0.12

NT Ext Equity Mkt Idx Fd - L 0.11

Fidelity Series Total Market Index 0.09

Spartan Extended Market Index Pool F 0.09

Vifag 2002 SICAV 0.08

DFA US Micro Cap I 0.07

Vanguard Instl Ttl Stck Mkt Idx Tr 0.07

NT Ext Equity Mkt Idx Fd - NL 0.07

Northern Trust Extended Eq Market Idx 0.07

Spartan Total Market Index Pool G 0.07

Schwab Total Stock Market Index 0.06

Vistagen Therapeutics Inc Market Status

Strong Buy: 3

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Vistagen Therapeutics Inc Fundamentals

Market Cap 23.68 M

PB Ratio 0.465

PE Ratio 0.0

Enterprise Value -36.67 M

Total Assets 84.34 M

Volume 512755

Vistagen Therapeutics Inc Company Financials

Annual Revenue FY25:486000 0.5M, FY24:1064000 1.1M, FY23:-227300 -0.2M, FY22:1108900 1.1M, FY21:1089500 1.1M

Annual Profit FY25:486000 0.5M, FY24:1064000 1.1M, FY23:-227300 -0.2M, FY22:1108900 1.1M, FY21:1089500 1.1M

Annual Net worth FY25:-51418000 -51.4M, FY24:-29362000 -29.4M, FY23:-59247700 -59.2M, FY22:-47762400 -47.8M, FY21:-17934200 -17.9M

Quarterly Revenue Q4/2025:303000 0.3M, Q3/2025:258000 0.3M, Q2/2025:244000 0.2M, Q1/2025:-15000 -0.0M, Q4/2024:234000 0.2M

Quarterly Profit Q4/2025:114000 0.1M, Q3/2025:258000 0.3M, Q2/2025:75000 0.1M, Q1/2025:-15000 -0.0M, Q4/2024:234000 0.2M

Quarterly Net worth Q4/2025:-18899000 -18.9M, Q3/2025:-19417000 -19.4M, Q2/2025:-15095000 -15.1M, Q1/2025:-13635000 -13.6M, Q4/2024:-14089000 -14.1M

About Vistagen Therapeutics Inc & investment objective

Company Information Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial to treat major depressive disorder. It also develops PH80, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase II clinical trial for the treatment to improve cognitive impairment caused by mental fatigue and potentially other disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial to treat loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. In addition, the company's clinical-stage pipeline consists of intranasal product candidates comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Organisation Biotechnology

Employees 59

Industry Biotechnology

CEO Mr. Shawn K. Singh J.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow